Six Hundredth Heart Attack Patient Recruited Into Phase III CicloMulsion CIRCUS Trial

NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heartreperfusion injury following stenting in patients with myocardial infarction.
Yahoo! News